Insider Buying: KindlyMD (NASDAQ:NAKA) CEO Purchases $309,746.30 in Stock

KindlyMD, Inc. (NASDAQ:NAKA) CEO David Bailey acquired 55,115 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were purchased at an average cost of $5.62 per share, with a total value of $309,746.30. Following the acquisition, the chief executive officer owned 3,175,476 shares of the company’s stock, valued at approximately $17,846,175.12. This represents a 1.77% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink.

KindlyMD Trading Up 11.8%

NASDAQ NAKA opened at $6.26 on Friday. The firm has a market cap of $108.92 million, a price-to-earnings ratio of -0.14 and a beta of 17.12. The company has a 50 day moving average of $8.14 and a 200-day moving average of $13.02. KindlyMD, Inc. has a 1-year low of $4.50 and a 1-year high of $995.60.

KindlyMD (NASDAQ:NAKA) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($15.20) earnings per share for the quarter. The firm had revenue of $2.68 million for the quarter. KindlyMD had a negative return on equity of 81.32% and a negative net margin of 7,397.12%. On average, analysts forecast that KindlyMD, Inc. will post -16.8 earnings per share for the current year.

KindlyMD News Roundup

Here are the key news stories impacting KindlyMD this week:

• Positive Sentiment: CEO David Bailey bought 31,500 more shares at $5.58, adding to a recent series of insider purchases that may reassure investors about the company’s outlook. Article Title
• Positive Sentiment: Maxim Group reiterated a Buy rating on NAKA with a $30 price target, and its newer earnings forecasts imply a possible improvement in results over time. Article Title
• Neutral Sentiment: The analyst estimates still call for losses in the next several quarters, though they show a potential path toward profitability in fiscal 2027. Article Title
• Negative Sentiment: KindlyMD’s latest reported quarter showed a large EPS loss and very weak profitability, underscoring that the business remains highly speculative despite the recent stock strength. Article Title

Analyst Ratings Changes

Several research firms have recently weighed in on NAKA. Wall Street Zen raised shares of KindlyMD to a “sell” rating in a report on Saturday, May 23rd. B. Riley Financial dropped their price objective on shares of KindlyMD from $40.00 to $20.00 and set a “buy” rating for the company in a report on Monday, February 23rd. Maxim Group dropped their price objective on shares of KindlyMD from $60.00 to $30.00 and set a “buy” rating for the company in a report on Monday, April 6th. TD Cowen assumed coverage on shares of KindlyMD in a report on Friday, April 10th. They set a “buy” rating and a $40.00 price objective for the company. Finally, Weiss Ratings raised shares of KindlyMD from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, May 11th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $30.00.

Institutional Trading of KindlyMD

Hedge funds and other institutional investors have recently modified their holdings of the stock. Osaic Holdings Inc. acquired a new stake in shares of KindlyMD in the second quarter valued at approximately $215,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of KindlyMD in the third quarter valued at approximately $369,000. Geode Capital Management LLC increased its holdings in shares of KindlyMD by 76.2% in the second quarter. Geode Capital Management LLC now owns 19,394 shares of the company’s stock valued at $484,000 after purchasing an additional 8,386 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of KindlyMD by 1,638.4% in the third quarter. Tower Research Capital LLC TRC now owns 33,152 shares of the company’s stock valued at $827,000 after purchasing an additional 31,245 shares in the last quarter. Finally, CI Investments Inc. acquired a new stake in shares of KindlyMD in the third quarter valued at approximately $995,000.

KindlyMD Company Profile

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.